ENDRA Life Sciences to Report First Quarter 2022 Financial Results on May 12, 2022
May 02 2022 - 08:00AM
Business Wire
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of
enhanced ultrasound technologies, today announced that the company
will report financial results for the first quarter of 2022 on
Thursday, May 12, 2022 after the close of trading on the U.S.
financial markets. Management will host a conference call and
webcast beginning at 4:30 p.m. Eastern time to discuss the results,
provide an update on recent corporate developments and answer
questions.
Participants are encouraged to pre-register for the conference
call using this link. Callers who pre-register will be given a
unique PIN to gain immediate access to the call and bypass the live
operator. Participants may register at any time, including up to
and after the call start time. Those unable to pre-register may
participate by dialing (844) 868-8846 (U.S.) or (412) 317-5465
(International). A webcast of the call may also be accessed at
ENDRA’s Investor Relations page and here.
A telephone replay will be available until May 19, 2022 by
dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and
providing the passcode 6511486. A webcast replay will be available
beginning approximately one hour after the completion of the live
conference call here.
About ENDRA Life Sciences Inc. ENDRA Life Sciences is the
pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a
ground-breaking technology being developed to visualize tissue like
MRI, but at 1/50th the cost and at the point of patient care.
TAEUS® is designed to work in concert with 400,000 cart-based
ultrasound systems in use globally today. TAEUS® is initially
focused on the measurement of fat in the liver as a means to assess
and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and
Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that
affect over one billion people globally, and for which there are no
practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit
www.endrainc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005013/en/
Company Contact: Irina Pestrikova Senior Director,
Finance investors@endrainc.com www.endrainc.com
Investor Relations Contact: Yvonne Briggs LHA Investor
Relations (310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Feb 2024 to Mar 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Mar 2023 to Mar 2024